LSE:OXB (Oxford BioMedica plc)
About OXB
Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focusses on the field of immunotherapy by managing a platform of technologies in designing gene-based medicines. The company operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of revenue from Europe.
Oxford BioMedica plc (LSE: OXB) Latest News
Investing Articles
AstraZeneca’s Covid-19 vaccine approved! Here’s what I’d do now
Investing Articles
Covid-19 vaccine: 1 biotech stock that profits from AstraZeneca’s success
Investing Articles
I’d buy these 2 growth stocks for explosive returns!
Investing Articles
Did Oxford Biomedica just find a new treatment for Parkinson’s disease?
Investing Articles
1 hidden growth stock I think can become a leader in this $14bn industry
Investing Articles
This biotech growth stock has soared in the coronavirus pandemic. Here’s what you need to know
Investing Articles
I believe this coronavirus stock could be a great growth opportunity
Investing Articles
Is the Thomas Cook share price a buy after 20% jump?
Investing Articles
Could this small-cap biotech stock beat the UKOG share price?
Investing Articles
One growth stock I’d buy alongside this Neil Woodford favourite
![](https://www.fool.co.uk/wp-content/uploads/2016/10/Growth-arrow--400x225.jpg)